Who are EQW plus DAPA's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Semaglutide, Empagliflozin, Exantide with Dapagliflozin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eqw-plus-dapa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

EQW plus DAPA — Competitive Intelligence Brief

EQW plus DAPA (EQW plus DAPA) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GLP-1 receptor agonist + SGLT2 inhibitor combination. Area: Diabetes.

phase 3 GLP-1 receptor agonist + SGLT2 inhibitor combination GLP-1 receptor; SGLT2 Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

EQW plus DAPA (EQW plus DAPA) — Woman's. EQW (semaglutide) is a GLP-1 receptor agonist combined with DAPA (dapagliflozin), an SGLT2 inhibitor, to provide dual glucose-lowering effects through incretin mimicry and urinary glucose excretion.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
EQW plus DAPA TARGET	EQW plus DAPA	Woman's	phase 3	GLP-1 receptor agonist + SGLT2 inhibitor combination	GLP-1 receptor; SGLT2
Semaglutide, Empagliflozin	Semaglutide, Empagliflozin	University Medical Center, Kazakhstan	marketed	GLP-1 receptor agonist + SGLT2 inhibitor combination	GLP-1 receptor; SGLT2
Exantide with Dapagliflozin	Exantide with Dapagliflozin	AstraZeneca	phase 3	GLP-1 receptor agonist / SGLT2 inhibitor combination	GLP-1 receptor; SGLT2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GLP-1 receptor agonist + SGLT2 inhibitor combination class)

University Medical Center, Kazakhstan · 1 drug in this class
Woman's · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EQW plus DAPA — Competitive Intelligence Brief. https://druglandscape.com/ci/eqw-plus-dapa. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab